Cytokinetics Inc (NASDAQ:CYTK) shares, rose in value on Thursday, March 27, with the stock price down by -1.47% to the previous day’s close as strong demand from buyers drove the stock to $42.99.
Actively observing the price movement in the last trading, the stock closed the session at $43.63, falling within a range of $42.68 and $44.44. The value of beta (5-year monthly) was 0.951. Referring to stock’s 52-week performance, its high was $75.71, and the low was $40.53. On the whole, CYTK has fluctuated by -8.26% over the past month.
With the market capitalization of Cytokinetics Inc currently standing at about $5.09 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-26.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 2.87M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CYTK’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CYTK currently trading nearly -2.47% and -6.22% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 43.36, while the 7-day volatility ratio is showing 5.99% which for the 30-day chart, stands at 5.24%. Furthermore, Cytokinetics Inc (CYTK)’s beta value is 0.90, and its average true range (ATR) is 2.33.
A comparison of Cytokinetics Inc (CYTK) with its peers suggests the former has fared considerably weaker in the market. CYTK showed an intraday change of -1.47% in last session, and over the past year, it shrunk by -37.45%%.
Data on historical trading for Cytokinetics Inc (NASDAQ:CYTK) indicates that the trading volumes over the past 10 days have averaged 1.8 and over the past 3 months, they’ve averaged 1.58 million. According to company’s latest data on outstanding shares, there are 118.21 million shares outstanding.
Nearly 2.52% of Cytokinetics Inc’s shares belong to company insiders and institutional investors own 109.79% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 14.22 million shares as on 2025-03-14, resulting in a short ratio of 7.82. According to the data, the short interest in Cytokinetics Inc (CYTK) stood at 1829.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 15.07 million. The stock has fallen by -8.61% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CYTK stock heading into the next quarter.
